Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or tia: A meta-analysis

Piero Verro, Phillip B. Gorelick, Danh Nguyen

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE - This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events. METHODS - We performed separate analyses of the incidences of stroke alone and composite outcome of stroke, myocardial infarction, or vascular death. We also performed two subset analyses, planned a priori, to examine effect size based on trials using (1) exclusively immediate-release and (2) predominantly extended-release dipyridamole. RESULTS - The summary results indicate a significant reduction in the overall risk ratio in favor of aspirin plus dipyridamole for stroke alone with relative risk 0.77 (0.67 to 0.89) and the composite end point with relative risk 0.85 (0.76 to 0.94). Studies using immediate-release dipyridamole showed a nonstatistically significant trend in favor of the combination for stroke alone with relative risk 0.83 (0.59 to 1.15) and for the composite outcome with relative risk 0.95 (0.75 to 1.19). Studies using predominantly extended-release dipyridamole showed a statistically significant difference in favor of the combination for stroke alone with relative risk 0.76 (0.65 to 0.89) and for the composite outcome with relative risk 0.82 (0.73 to 0.92). CONCLUSIONS - The combination of aspirin plus dipyridamole is more effective than aspirin alone in preventing stroke and other serious vascular events in patients with minor stroke and TIAs. The risk reduction was greater and statistically significant for studies using primarily extended release dipyridamole, which may reflect a true pharmacological effect or lack of statistical power in studies using immediate release dipyridamole.

Original languageEnglish (US)
Pages (from-to)1358-1363
Number of pages6
JournalStroke
Volume39
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Dipyridamole
Aspirin
Blood Vessels
Meta-Analysis
Stroke
Risk Reduction Behavior
Randomized Controlled Trials
Odds Ratio
Myocardial Infarction
Pharmacology
Incidence

Keywords

  • Antiplatelet drugs
  • Cerebrovascular accident
  • Prevention
  • Stroke management
  • Transient ischemic attack

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or tia : A meta-analysis. / Verro, Piero; Gorelick, Phillip B.; Nguyen, Danh.

In: Stroke, Vol. 39, No. 4, 04.2008, p. 1358-1363.

Research output: Contribution to journalArticle

Verro, Piero ; Gorelick, Phillip B. ; Nguyen, Danh. / Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or tia : A meta-analysis. In: Stroke. 2008 ; Vol. 39, No. 4. pp. 1358-1363.
@article{9fc0a8518a094de498605dbf78bc26de,
title = "Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or tia: A meta-analysis",
abstract = "BACKGROUND AND PURPOSE - This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events. METHODS - We performed separate analyses of the incidences of stroke alone and composite outcome of stroke, myocardial infarction, or vascular death. We also performed two subset analyses, planned a priori, to examine effect size based on trials using (1) exclusively immediate-release and (2) predominantly extended-release dipyridamole. RESULTS - The summary results indicate a significant reduction in the overall risk ratio in favor of aspirin plus dipyridamole for stroke alone with relative risk 0.77 (0.67 to 0.89) and the composite end point with relative risk 0.85 (0.76 to 0.94). Studies using immediate-release dipyridamole showed a nonstatistically significant trend in favor of the combination for stroke alone with relative risk 0.83 (0.59 to 1.15) and for the composite outcome with relative risk 0.95 (0.75 to 1.19). Studies using predominantly extended-release dipyridamole showed a statistically significant difference in favor of the combination for stroke alone with relative risk 0.76 (0.65 to 0.89) and for the composite outcome with relative risk 0.82 (0.73 to 0.92). CONCLUSIONS - The combination of aspirin plus dipyridamole is more effective than aspirin alone in preventing stroke and other serious vascular events in patients with minor stroke and TIAs. The risk reduction was greater and statistically significant for studies using primarily extended release dipyridamole, which may reflect a true pharmacological effect or lack of statistical power in studies using immediate release dipyridamole.",
keywords = "Antiplatelet drugs, Cerebrovascular accident, Prevention, Stroke management, Transient ischemic attack",
author = "Piero Verro and Gorelick, {Phillip B.} and Danh Nguyen",
year = "2008",
month = "4",
doi = "10.1161/STROKEAHA.107.496281",
language = "English (US)",
volume = "39",
pages = "1358--1363",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or tia

T2 - A meta-analysis

AU - Verro, Piero

AU - Gorelick, Phillip B.

AU - Nguyen, Danh

PY - 2008/4

Y1 - 2008/4

N2 - BACKGROUND AND PURPOSE - This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events. METHODS - We performed separate analyses of the incidences of stroke alone and composite outcome of stroke, myocardial infarction, or vascular death. We also performed two subset analyses, planned a priori, to examine effect size based on trials using (1) exclusively immediate-release and (2) predominantly extended-release dipyridamole. RESULTS - The summary results indicate a significant reduction in the overall risk ratio in favor of aspirin plus dipyridamole for stroke alone with relative risk 0.77 (0.67 to 0.89) and the composite end point with relative risk 0.85 (0.76 to 0.94). Studies using immediate-release dipyridamole showed a nonstatistically significant trend in favor of the combination for stroke alone with relative risk 0.83 (0.59 to 1.15) and for the composite outcome with relative risk 0.95 (0.75 to 1.19). Studies using predominantly extended-release dipyridamole showed a statistically significant difference in favor of the combination for stroke alone with relative risk 0.76 (0.65 to 0.89) and for the composite outcome with relative risk 0.82 (0.73 to 0.92). CONCLUSIONS - The combination of aspirin plus dipyridamole is more effective than aspirin alone in preventing stroke and other serious vascular events in patients with minor stroke and TIAs. The risk reduction was greater and statistically significant for studies using primarily extended release dipyridamole, which may reflect a true pharmacological effect or lack of statistical power in studies using immediate release dipyridamole.

AB - BACKGROUND AND PURPOSE - This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events. METHODS - We performed separate analyses of the incidences of stroke alone and composite outcome of stroke, myocardial infarction, or vascular death. We also performed two subset analyses, planned a priori, to examine effect size based on trials using (1) exclusively immediate-release and (2) predominantly extended-release dipyridamole. RESULTS - The summary results indicate a significant reduction in the overall risk ratio in favor of aspirin plus dipyridamole for stroke alone with relative risk 0.77 (0.67 to 0.89) and the composite end point with relative risk 0.85 (0.76 to 0.94). Studies using immediate-release dipyridamole showed a nonstatistically significant trend in favor of the combination for stroke alone with relative risk 0.83 (0.59 to 1.15) and for the composite outcome with relative risk 0.95 (0.75 to 1.19). Studies using predominantly extended-release dipyridamole showed a statistically significant difference in favor of the combination for stroke alone with relative risk 0.76 (0.65 to 0.89) and for the composite outcome with relative risk 0.82 (0.73 to 0.92). CONCLUSIONS - The combination of aspirin plus dipyridamole is more effective than aspirin alone in preventing stroke and other serious vascular events in patients with minor stroke and TIAs. The risk reduction was greater and statistically significant for studies using primarily extended release dipyridamole, which may reflect a true pharmacological effect or lack of statistical power in studies using immediate release dipyridamole.

KW - Antiplatelet drugs

KW - Cerebrovascular accident

KW - Prevention

KW - Stroke management

KW - Transient ischemic attack

UR - http://www.scopus.com/inward/record.url?scp=41149144263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149144263&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.107.496281

DO - 10.1161/STROKEAHA.107.496281

M3 - Article

C2 - 18323511

AN - SCOPUS:41149144263

VL - 39

SP - 1358

EP - 1363

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 4

ER -